HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study

Boehringer Ingelheim and Zai Lab have entered into a clinical collaboration to investigate a dual DLL3-targeting approach for patients with ES-SCLC and other NECs.

By Pharmaceutical Technology · Apr 16, 2026 · via Pharmaceutical Technology
Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study

Image: Pharmaceutical Technology

Tags
theweekformat:headlineheadlinePharmaceutical Technology
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
In industry's latest OTC pivot, Daiichi Sankyo lines up $1.5B consumer health unit sale to beverage giant Suntory
DealsFiercePharma ↗
In industry's latest OTC pivot, Daiichi Sankyo lines up $1.5B consumer health unit sale to beverage giant Suntory
With Daiichi Sankyo’s priorities increasingly tied to its innovative medicines—and its oncology portfolio in p…
Apr 17, 2026
UCB Buys Neurona for $650M, Bets on Regenerative Medicine and Epilepsy Cell Therapy
DealsBriefing
UCB Buys Neurona for $650M, Bets on Regenerative Medicine and Epilepsy Cell Therapy
UCB’s $650M-plus purchase of Neurona Therapeutics signals a move beyond small molecules into regenerative neur…
Apr 17, 2026
Novo Nordisk Bets on OpenAI to Accelerate Drug Development
DealsBriefing
Novo Nordisk Bets on OpenAI to Accelerate Drug Development
Novo Nordisk unveiled a global AI collaboration with OpenAI, extending from drug discovery to manufacturing as…
Apr 17, 2026